The upcoming report from Medical Properties (MPW) is expected to reveal quarterly earnings of $0.25 per share, indicating a decline of 32.4% compared to the year-ago period. Analysts forecast revenues of $283.29 million, representing a decrease of 19.1% year over year. The consensus EPS estimate for the quarter has been revised 9.6% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe. Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock. While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight. That said, let's delve into the average estimates of some Medical Properties metrics that Wall Street analysts commonly model and monitor. The consensus estimate for 'Revenues- Straight-line rent' stands at $42.26 million. The estimate points to a change of -25.5% from the year-ago quarter. Analysts' assessment points toward 'Revenues- Interest and other income' reaching $23.09 million. The estimate indicates a year-over-year change of -28.2%. Based on the collective assessment of analysts, 'Revenues- Rent billed' should arrive at $205.02 million. The estimate suggests a change of -17.4% year over year. Analysts predict that the 'Revenues- Income from financing leases' will reach $20.41 million. The estimate indicates a change of +54.6% from the prior-year quarter. Analysts forecast 'Real estate depreciation and amortization' to reach $79.97 million. The estimate compares to the year-ago value of $83.86 million. View all Key Company Metrics for Medical Properties here>>> Over the past month, Medical Properties shares have recorded returns of +7.8% versus the Zacks S&P 500 composite's -4% change. Based on its Zacks Rank #3 (Hold), MPW will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medical Properties Trust, Inc. (MPW):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Wall Street's Insights Into Key Metrics Ahead of Medical Properties (MPW) Q1 Earnings
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...